WO2013130577A3 - Compositions and methods for the treatment of migraine - Google Patents
Compositions and methods for the treatment of migraine Download PDFInfo
- Publication number
- WO2013130577A3 WO2013130577A3 PCT/US2013/027983 US2013027983W WO2013130577A3 WO 2013130577 A3 WO2013130577 A3 WO 2013130577A3 US 2013027983 W US2013027983 W US 2013027983W WO 2013130577 A3 WO2013130577 A3 WO 2013130577A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- migraine
- treatment
- alpha
- compositions
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2865593A CA2865593A1 (en) | 2012-02-27 | 2013-02-27 | Compositions and methods for the treatment of migraine |
EP13754567.9A EP2819674A2 (en) | 2012-02-27 | 2013-02-27 | Compositions and methods for the treatment of migraine |
JP2014558959A JP2015517980A (en) | 2012-02-27 | 2013-02-27 | Compositions and methods for the treatment of migraine |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/406,321 | 2012-02-27 | ||
US13/406,321 US20120156244A1 (en) | 2008-08-01 | 2012-02-27 | Nasal Compositions and Uses Thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013130577A2 WO2013130577A2 (en) | 2013-09-06 |
WO2013130577A3 true WO2013130577A3 (en) | 2015-03-12 |
Family
ID=49083441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2013/027983 WO2013130577A2 (en) | 2012-02-27 | 2013-02-27 | Compositions and methods for the treatment of migraine |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2819674A2 (en) |
JP (1) | JP2015517980A (en) |
CA (1) | CA2865593A1 (en) |
WO (1) | WO2013130577A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020259440A1 (en) * | 2019-06-28 | 2020-12-30 | 四川普锐特药业有限公司 | Nasal spray of dexmedetomidine, preparation method therefor and use thereof |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9795560B2 (en) | 2013-02-01 | 2017-10-24 | Ocularis Pharma, Llc | Aqueous ophthalmic solutions of phentolamine and medical uses thereof |
CA2899342C (en) | 2013-02-01 | 2021-09-21 | Ocularis Pharma, Llc | Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance |
EP3562486B1 (en) | 2016-12-31 | 2024-03-13 | Bioxcel Therapeutics, Inc. | Use of sublingual dexmedetomidine for the treatment of agitation |
AU2018380300B2 (en) * | 2017-12-08 | 2022-06-16 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
EP3813802A4 (en) | 2018-06-27 | 2022-06-08 | Bioxcel Therapeutics, Inc. | Film formulations containing dexmedetomidine and methods of producing them |
SG11202104094YA (en) | 2018-10-26 | 2021-05-28 | Ocuphire Pharma Inc | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders |
MX2022000709A (en) | 2019-07-19 | 2022-05-19 | Bioxcel Therapeutics Inc | Non-sedating dexmedetomidine treatment regimens. |
CN115368310A (en) | 2021-05-18 | 2022-11-22 | 奥库菲尔医药公司 | Method for synthesizing phentolamine mesylate |
US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6486190B1 (en) * | 1997-11-24 | 2002-11-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability |
US20020192288A1 (en) * | 2000-06-26 | 2002-12-19 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
US20090220611A1 (en) * | 2005-09-30 | 2009-09-03 | Frederic Dargelas | Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same |
US20110021588A1 (en) * | 2009-05-15 | 2011-01-27 | Recro Pharma, Inc. | Sublingual dexmeditomidine compositions and methods of use thereof |
US20110257188A1 (en) * | 2008-08-01 | 2011-10-20 | Gerald Horn | Compositions and methods for the treatment of nasal conditions |
-
2013
- 2013-02-27 JP JP2014558959A patent/JP2015517980A/en active Pending
- 2013-02-27 EP EP13754567.9A patent/EP2819674A2/en not_active Withdrawn
- 2013-02-27 WO PCT/US2013/027983 patent/WO2013130577A2/en active Application Filing
- 2013-02-27 CA CA2865593A patent/CA2865593A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6486190B1 (en) * | 1997-11-24 | 2002-11-26 | The Procter & Gamble Company | 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability |
US20020192288A1 (en) * | 2000-06-26 | 2002-12-19 | Williams Robert O. | Methods and compositions for treating pain of the mucous membrane |
US20090220611A1 (en) * | 2005-09-30 | 2009-09-03 | Frederic Dargelas | Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same |
US20110257188A1 (en) * | 2008-08-01 | 2011-10-20 | Gerald Horn | Compositions and methods for the treatment of nasal conditions |
US20110021588A1 (en) * | 2009-05-15 | 2011-01-27 | Recro Pharma, Inc. | Sublingual dexmeditomidine compositions and methods of use thereof |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020259440A1 (en) * | 2019-06-28 | 2020-12-30 | 四川普锐特药业有限公司 | Nasal spray of dexmedetomidine, preparation method therefor and use thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2015517980A (en) | 2015-06-25 |
CA2865593A1 (en) | 2013-09-06 |
EP2819674A2 (en) | 2015-01-07 |
WO2013130577A2 (en) | 2013-09-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013130577A3 (en) | Compositions and methods for the treatment of migraine | |
WO2010037059A3 (en) | Heteroaryl antagonists of prostaglandin d2 receptors | |
WO2008021851A3 (en) | Novel compounds as antagonists or inverse agonists for opioid receptors | |
WO2010039977A3 (en) | Heteroaryl antagonists of prostaglandin d2 receptors | |
WO2009108720A3 (en) | Antagonists of prostaglandin d2 receptors | |
WO2010077882A3 (en) | Antagonists of lysophosphatidic acid receptors | |
UA98839C2 (en) | N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors | |
WO2010057118A3 (en) | Heterocyclic antagonists of prostaglandin d2 receptors | |
WO2011103202A3 (en) | Androgen receptor modulators and uses thereof | |
WO2010003127A3 (en) | Antagonists of prostaglandin d2 receptors | |
WO2012037411A3 (en) | Estrogen receptor modulators and uses thereof | |
PH12014501351B1 (en) | Fluorinated estrogen receptor modulators and uses thereof | |
WO2009102893A3 (en) | Cyclic diaryl ether compounds as antagonists of prostaglandin d2 receptors | |
WO2010042652A3 (en) | Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors | |
WO2010068775A3 (en) | Alkyne antagonists of lysophosphatidic acid receptors | |
WO2010141768A3 (en) | Polycyclic antagonists of lysophosphatidic acid receptors | |
TN2014000030A1 (en) | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as c5a receptor modulators | |
WO2011159769A3 (en) | Indane estrogen receptor modulators and uses thereof | |
WO2012021629A3 (en) | Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease | |
WO2008021849A3 (en) | Novel compounds as antagonists or inverse agonists at opioid receptors | |
WO2009145989A3 (en) | Aminoalkylphenyl antagonists of prostaglandin d2 receptors | |
WO2009115547A8 (en) | Trisubstituted 1, 2, 4 -triazoles as nicotinic acetylcholine receptor modulators | |
EP3632444A3 (en) | Topical lfa-1 antagonists for use in localized treatment of immune related disorders | |
WO2008121348A3 (en) | Peripheral opioid receptor antagonists and uses thereof | |
WO2010085820A3 (en) | Tricyclic compounds as antagonists of prostaglandin d2 receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13754567 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2865593 Country of ref document: CA Ref document number: 2014558959 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013754567 Country of ref document: EP |